Aerska, a Dublin-based biotech company working to prevent brain disease, announced a $39 million round of Series A funding to advance its technology. EQT Dementia Fund and age1 led the round that brings Aerska’s total raised capital to $60 million.
Designed to overcome the historically challenging blood-brain barrier, the company’s unique approach works to deliver RNA medicines directly to the source of a patient’s neurological disease. Aerska’s proprietary “brain shuttle” technology enables intravenous or subcutaneous administration and distributes medicine consistently throughout the brain while reliably taking down the targeted gene.
“The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration,” Jack O’Meara, Aerska’s CEO and co-founder, said in a statement. “Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically driven forms of Alzheimer’s disease and other devastating brain disorders.”
Aerska will put its latest capital raise toward continuing development of its antibody-oligo conjugate platform as it strives toward clinical approval.
